Patients already taking triple inhaled therapy still average 1.1 moderate or severe exacerbations annually.2
Please note: Axenil Labs operates in a stealth capacity.
Name
Corporate email
Nature of inquiryPlease selectStrategic partneringInvestment inquiriesGeneral inquiries
This goes to the founding team, not to a list. Your details go no further than the reply. Privacy notice.